The United Kingdom and the United States have hammered out a major bilateral deal that will guarantee no import taxes on British medicine shipments going into the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has agreed to boost funding on drugs through the public health system. This commitment guarantees that import taxes on these vital goods will remain at zero for a timeframe of three years.
This development comes after recent statements to dramatically increase duties on branded drug products, with increases discussed reaching double the cost.
"This agreement between the United Kingdom reinforces the international landscape for innovative medicines and brings long-overdue equity to U.S.–U.K. drug exports," a release noted.
Economic Importance
Drugs constitute one of the Britain's largest export categories to the US, which is clearly the biggest destination for leading UK drugmakers.
Statistics indicate that in the year leading up to the third quarter, the UK shipped drugs worth billions to the US. This amount made up 17.4% of all goods exports in that period.
"This guarantee protects jobs, stimulates investment and sets the stage for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary stated.
Detailed British Pledges
The deal entails several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to raise overall health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum drug companies must refund to the NHS to prevent overspending will be limited at 15%. In the past, rebates were more than 20%.
Broader Context
The deal follows a ongoing dispute between the drug companies and the British authorities over drug pricing and regulatory access.
The disagreement were exacerbated by claims that US patients were paying significantly more for the equivalent treatments than people in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar investments have been directed toward US facilities.
One official publicly accepted that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the last ten years.
